Loading
A phase 2 trial of Lifileucel in endometrial cancer, run by Iovance Biotherapeutics, Inc., now recruiting.
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. is a phase 2 interventional study registered as NCT06481592 by Iovance Biotherapeutics, Inc., with 60 participants planned, started 2024-10-29 and due to reach its primary completion in 2028-05. Interventions recorded: Lifileucel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Lifileucel, TIL therapy.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Lifileucel, TIL therapy.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/